Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Trist

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Pharmacology|December 4, 2018
EditorialDavid Trist, Mike Williams
Current Opinion in Pharmacology|December 4, 2018
EditorialDavid Trist, Mike Williams
Current Opinion in Pharmacology|December 15, 2019
EditorialMichael Williams, David Trist
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 17, 2008
Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responsesDavid Walker, Yong Yang, Emiliangelo Ratti, et al.
Behavioural Pharmacology|August 14, 2009
Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbilsScott A Heldt, Michael Davis, Emiliangelo Ratti, et al.
Journal of Clinical Psychopharmacology|October 25, 2011
Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorderEmiliangelo Ratti, Kevin Bellew, Paolo Bettica, et al.
Journal of Psychopharmacology (Oxford, England)|March 30, 2013
Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studiesEmiliangelo Ratti, Paolo Bettica, Robert Alexander, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Pharmacology|December 4, 2018
EditorialDavid Trist, Mike Williams
Current Opinion in Pharmacology|December 4, 2018
EditorialDavid Trist, Mike Williams
Current Opinion in Pharmacology|December 15, 2019
EditorialMichael Williams, David Trist
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 17, 2008
Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responsesDavid Walker, Yong Yang, Emiliangelo Ratti, et al.
Behavioural Pharmacology|August 14, 2009
Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbilsScott A Heldt, Michael Davis, Emiliangelo Ratti, et al.
Journal of Clinical Psychopharmacology|October 25, 2011
Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorderEmiliangelo Ratti, Kevin Bellew, Paolo Bettica, et al.
Journal of Psychopharmacology (Oxford, England)|March 30, 2013
Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studiesEmiliangelo Ratti, Paolo Bettica, Robert Alexander, et al.
Pageof 1